公开(公告)号：US11040026B2

公开(公告)日：2021-06-22

申请号：US16327742

申请日：2017-08-31

Applicant: SUVEN LIFE SCIENCES LIMITED

Inventor： Ramakrishna Nirogi ,  Anil Karbhari Shinde ,  Abdul Rasheed Mohammed ,  Rajesh Kumar Badange ,  Pradeep Jayarajan ,  Gopinadh Bhyrapuneni ,  Venkateswarlu Jasti

IPC: A61K31/437 ,  A61P25/28 ,  A61K31/13 ,  A61K31/325 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/445 ,  A61K31/473 ,  A61K31/5383 ,  A61K31/55 ,  C07D471/04 ,  C07D491/056 ,  C07D498/04

Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt(s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).

公开(公告)号：US12156871B2

公开(公告)日：2024-12-03

申请号：US16766112

申请日：2018-11-21

Applicant: SUVEN LIFE SCIENCES LIMITED

Inventor： Ramakrishna Nirogi ,  Anil Karbhari Shinde ,  Abdul Rasheed Mohammed ,  Rajesh Kumar Badange ,  Raghava Choudary Palacharla ,  Venkateswarlu Jasti

IPC: A61P25/28 ,  A61K31/13 ,  A61K31/27 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/445 ,  A61K31/473 ,  A61K31/55 ,  C07D471/04

Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the methods of preparation, pharmaceutical composition, combinations and the use of compound formula (I), their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof.

公开(公告)号：US10973831B2

公开(公告)日：2021-04-13

申请号：US16635893

申请日：2018-08-06

Applicant: SUVEN LIFE SCIENCES LIMITED

Inventor： Ramakrishna Nirogi ,  Anil Karbhari Shinde ,  Abdul Rasheed Mohammed ,  Rajesh Kumar Badange ,  Kumar Bojja ,  Vinod Kumar Goyal ,  Santosh Kumar Pandey ,  Jagadeesh Babu Thentu ,  Venkateswarlu Jasti

IPC: A61K31/538 ,  A61P25/28 ,  C07D413/04 ,  C07D413/14 ,  A61K31/13 ,  A61K31/24 ,  A61K31/445 ,  A61K31/473 ,  A61K31/155

Abstract: The present invention relates to fluoropiperidine compounds of formula (I), their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof as 5-HT6 receptor antagonists. In particular the present invention discloses the methods of preparation, pharmaceutical composition, combinations and use of fluoropiperidine compounds, their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof.